SAN JOSE, California, March 3, 2020 /PRNewswire-HISPANIC PR WIRE/ — Outset Medical, a leading med tech innovator delivering first-of-its-kind technology into the growing global dialysis market, today announced the appointment of James Hinrichs to its Board of Directors. In addition to his board service, Mr. Hinrichs will serve as Chair of the company’s Audit Committee.
“We are thrilled to have Jim join our Board of Directors,” said Outset Medical CEO, Leslie Trigg. “With a 30-year track record of both private and public company success, his governance and financial operations experience in high-growth environments will be invaluable to Outset.”
Mr. Hinrichs has held the role of Chief Financial Officer at multiple companies including Alere Inc. until its sale to Abbott Labs, and CareFusion Corporation until its sale to Becton Dickinson. Mr. Hinrichs also currently serves as a director of Orthofix Inc., Integer Holdings, Acutus Medical and Cibus. He holds undergraduate and graduate degrees in business from Carnegie Mellon University.
“Outset is poised for significant growth, and I’m incredibly excited to join their board,” said Mr. Hinrichs. “The expanded commercialization of Tablo will give providers much needed innovation to reduce the cost and complexity of delivering dialysis.”
Dialysis is delivered to more than 550,000 U.S. patients several times per week to remove waste products and excess fluid from patients with kidney failure. Although more than 85 million dialysis treatments take place in the United States each year at an estimated annual cost of ~$75 billion, little meaningful technology or service model innovation has been introduced in decades.
Outset Medical’s Tablo was designed as an enterprise solution to reduce the cost and complexity of dialysis, while improving the experience for patients and providers. With real-time water purification and dialysis fluid production integrated in a single, compact system, Tablo functions like a dialysis clinic on wheels. Requiring just an electrical outlet and tap water to operate, Tablo frees providers from having to rely on expensive clinic infrastructure, enabling on-demand, cost-effective dialysis in a range of use environments. Tablo was designed to look and feel like an intuitive consumer product, keeping end-user simplicity in mind. Wireless data, sensor-based automation, and an animated touchscreen make Tablo easy to learn and use for healthcare professionals and patients alike.
About Outset Medical
Outset Medical is dedicated to delivering patient-centered dialysis through service model and technology innovation aimed at reducing cost and transforming the patient care experience. Outset’s Tablo® System is FDA-cleared and CE-marked for use in acute and chronic care settings. In addition to its acute and chronic care commercial expansion, the company is conducting a clinical trial exploring the use of Tablo for home dialysis. For more information, visit www.outsetmedical.com and follow the company on Twitter at @OutsetMedical.
SOURCE Outset Medical, Inc.
